Safety First: Fractional Nonablative Laser Resurfacing in Fitzpatrick Skin Types IV to VI

April 15, 2013 | Category: Lasers, Pigmentation disorders
Safety First: Fractional Nonablative Laser Resurfacing in Fitzpatrick Skin Types IV to VI

Anthony M. Rossi, MD

Dr. Rossi is a Fellow in Procedural Dermatology and Mohs Surgery, Memorial Sloan-Kettering and Weill Cornell/New York-Presbyterian Hospital, both in New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

 

In the April 2013 issue of the Journal of Drugs in Dermatology (2013;12:428-431), Clark et al retrospectively reviewed 115 laser sessions with the 1550-nm erbium-doped fractional nonablative laser (Fraxel Re:Store SR 1550, Solta Medical) in 45 patients with Fitzpatrick skin types IV to VI to assess the rate of postinflammatory hyperpigmentation and the associated laser parameters. The fluence, treatment level, and number of passes were all reviewed, as well as any posttreatment complications (ie, erythema, blistering, edema, bruising, pain) and long-term (1 month) complications (ie, hypopigmentation, hyperpigmentation).

[More]

AAD 2013 Miami Highlights: A Resident’s Perspective

April 03, 2013 | Category: Dermatologic agents
AAD 2013 Miami Highlights: A Resident’s Perspective

Brooke Walls, DO
Dr. Walls is from Nova Southeastern University College of Osteopathic Medicine, Largo, Florida.
Dr. Walls reports no conflicts of interest in relation to this post.

 

One of the challenges of the American Academy of Dermatology (AAD) annual meeting is attending all the lectures that spark your interest while trying to attend lectures that offer a variety of topics. Many of the lectures that you want to attend are offered at the same time and there is just no way to attend every lecture that is appealing. The dermatology review 2-day course (C009) is the answer to this problem.

[More]

TCA and Phenol Peels: What Can We Learn From Photoaged Hairless Mice?

April 02, 2013 | Category: Anti-aging treatments, Cosmetic dermatology
TCA and Phenol Peels: What Can We Learn From Photoaged Hairless Mice?

Gary Goldenberg, MD

Dr. Goldenberg is Assistant Professor, Department of Dermatology, Mount Sinai School of Medicine, New York, New York, and Medical Director of the Dermatology Faculty Practice, New York (http://www.goldenbergdermatology.com).

Dr. Goldenberg reports no conflicts of interest in relation to this post.

 

A study published in the International Journal of Dermatology (2011;50:1075-1082) evaluated skin rejuvenation effects of trichloroacetic acid (TCA) and phenol peels in photoaged hairless mice. Photoaged skin exhibits deep coarse wrinkles, dryness, telangiectasia, skin atrophy, and hyperpigmentation. Three types of chemical peels are currently used: superficial type, penetrates and damages the papillary dermis (TCA 10%–30%); medium type, penetrates and damages the upper reticular dermis (TCA 50%); deep type, penetrates and damages the lower reticular dermis (phenol, Baker-Gordon peel formula). The mechanism by which peels improve photoaged properties of skin is not fully understood. 

[More]

An Aspirin a Day Keeps Melanoma Away?

April 01, 2013 | Category: Melanoma, Scientific research
An Aspirin a Day Keeps Melanoma Away?

Lorraine L. Rosamilia, MD

Dr. Rosamilia is from the Department of Dermatology, Geisinger Health System, State College, Pennsylvania.

Dr. Rosamilia reports no conflicts of interest in relation to this post.

 

Cancer recently reported dermatologically germane data from the Women’s Health Initiative Observational Study in which a large cohort of postmenopausal white women aged 50 to 79 years were followed by health questionnaire and clinic visits at 40 national sites over 12 years, highlighting risk factors and associations with heart disease, cancer, and fractures. In a subset of nearly 60,000 women in the study, 548 incident melanomas were confirmed, and data regarding skin type, sun exposure, skin cancer history, and medication use were analyzed.

[More]

Smartphones: Not Smart Enough for Melanoma

February 25, 2013 | Category: Melanoma
Smartphones: Not Smart Enough for Melanoma

Lorraine L. Rosamilia, MD

Dr. Rosamilia is from the Department of Dermatology, Geisinger Health System, State College, Pennsylvania.

Dr. Rosamilia reports no conflicts of interest in relation to this post.

 

JAMA Dermatology recently published a case-control study from the University of Pittsburgh wherein 4 smartphone applications (apps) designed to aid consumers in determining if a skin lesion is benign or malignant were put to the test. Digital images taken by dermatologists of 60 melanomas and 128 benign control lesions (prior to skin biopsy and dermatopathologist-determined diagnosis) were uploaded into these consumer apps, and there was a very broad range of diagnostic sensitivity and specificity.

[More]

Punctuated 88% Phenol Peels in the Treatment of Photoaging: Old Peel, New Technique

February 20, 2013 | Category: Cosmetic dermatology, Dermatologic procedures/surgery
Punctuated 88% Phenol Peels in the Treatment of Photoaging: Old Peel, New Technique

Anthony M. Rossi, MD

Dr. Rossi is a Fellow in Procedural Dermatology and Mohs Surgery, Memorial Sloan-Kettering and Weill Cornell/New York-Presbyterian Hospital, both in New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

 

The December 2012 issue of Dermatologic Surgery (2012;38:2011-2015) contained a histopathologic case study of 3 patients with facial wrinkles treated with an in-office 88% phenol peel based in a punctuated fashion. The 88% phenol peel was applied in a localized dot manner with a toothpick soaked in phenol solution. The dots were separated by 3 mm along the length of the facial wrinkles. None of the patients were sedated and there was no patient downtime seen. This same procedure also was performed on the preauricular region.

[More]

Are There Clinical Studies Supporting the Use of Homeopathic Medicine in Modern Dermatology?

February 04, 2013 | Category: Dermatologic agents, Dermatologic therapy

Robert J. Signore, DO

Dr. Signore is in private practice, Tinley Park, Illinois.

Dr. Signore reports no conflicts of interest in relation to this post.

 

Homeopathic medicine (HM) is one of the most widely used forms of complementary medicine in the world.1 It is a low-cost nontoxic system of natural healing used by millions of people worldwide.2 According to the Centers for Disease Control and Prevention’s National Center for Health Statistics, US adults spent $2.9 billion out-of-pocket on the purchase of HMs in 2007.3 Homeopathic medicine differs from herbal medicine in that HM does not contain substantial pharmacologic amounts of active substances in commonly used dilutions. Hence HMs do not interact with conventional drugs.1 Homeopathic medicines are regulated by the US Food and Drug Administration as drugs per the Federal Food, Drug, and Cosmetic Act.4 The mechanism of action of HM is unknown.

 

But the world of medicine revolves around scientific research! Are there any clinical studies to support the use of HM in modern dermatology?

[More]

Compassion in Dermatology: The Rules of Engagement

December 18, 2012 | Category: Patient-doctor relationship, Practice management
Compassion in Dermatology: The Rules of Engagement

Philip R. Cohen, MD

Dr. Cohen is from the University of Houston Health Center, Texas; the Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston; and the Department of Dermatology, University of Texas Medical School, Houston.

Dr. Cohen reports no conflicts of interest in relation to this post.

 

In a succinct paper, Shaw (Int J Dermatol. 2012;51:113-114) outlined not only appropriate clinic etiquette and diagnostic tips but also a humanistic approach to interacting with patients. He commented that patients are often frightened and emotionally fragile about their diagnosis; in addition, they receive a lot of information during the visit with varying needs for supplemental explanation and may not understand the dermatologic vocabulary used by physicians. He also emphasized the physician’s responsibility in helping the patient by being serious and caring.

[More]

Liquid Facelift With Sculptra

Liquid Facelift With Sculptra

Gary Goldenberg, MD

Dr. Goldenberg is Assistant Professor, Department of Dermatology, Mount Sinai School of Medicine, New York, New York, and Medical Director of the Dermatology Faculty Practice, New York (http://www.goldenbergdermatology.com).

Dr. Goldenberg reports no conflicts of interest in relation to this post.

 

A review published in the Aesthetic Surgery Journal (2011;31:95-109) highlighted the use of poly-L-lactic acid (PLLA)(Sculptra Aesthetic, Valeant Aesthetics, a division of Valeant Pharmaceuticals North America) for nonsurgical rejuvenation of the aging face and restoration of facial volume. The nonsurgical, or liquid, facelift has become increasingly popular and use of PLLA is one of the cornerstones of this procedure.  

[More]

Dosing of OnabotulinumtoxinA for Hyperdynamic Perioral Rhytides

Dosing of OnabotulinumtoxinA for Hyperdynamic Perioral Rhytides

Anthony M. Rossi, MD

Dr. Rossi is a Fellow in Procedural Dermatology and Mohs Surgery, Memorial Sloan-Kettering and Weill Cornell/New York-Presbyterian Hospital, both in New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

 

The September 2012 issue of Dermatologic Surgery (2012;38:1497-1505) featured a randomized double-blind study to compare the safety, efficacy, and dose-response relationship of 2 doses of onabotulinumtoxinA for the treatment of hyperdynamic perioral rhytides. Sixty female participants were randomized in a 1:1 ratio to receive either 7.5 or 12.0 U of onabotulinumtoxinA at 4 perioral sites. Participants were then assessed at weeks 2, 4, 8, 12, 16, and 20. The severity of the perioral lines and participant satisfaction were assessed at all visits.

[More]

Month List

Tag Cloud